Therapeutic Area
About 10% of people worldwide suffer from chronic kidney disease. However, no matter at home or abroad, so far, no innovative drug has been approved and marketed for chronic kidney disease. This represents a huge unmet medical need for the nearly 700 million chronic kidney disease patients worldwide.
With the gradual improvement of human living standards, infectious diseases (diseases caused by microorganisms, parasites, etc.) have been gradually controlled, resulting in a gradual increase in the average life expectancy of human beings, but the impact of tumors on health and quality of life continues to increase. With the exponential accumulation of knowledge and technological breakthroughs in the biomedical field, the company will move from discovery of novel targets, development and optimization of lead compounds, and clinical trials of new drugs to final realization.